Ani Pharmaceuticals Inc (NASDAQ:ANIP) Sentiment Change Report

June 14, 2018 - By Carrie Sands

Sentiment for Ani Pharmaceuticals Inc (NASDAQ:ANIP)

Ani Pharmaceuticals Inc (NASDAQ:ANIP) institutional sentiment increased to 1.43 in Q1 2018. Its up 0.34, from 1.09 in 2017Q4. The ratio has improved, as 77 institutional investors opened new or increased stock positions, while 54 sold and decreased their stock positions in Ani Pharmaceuticals Inc. The institutional investors in our partner’s database now own: 6.72 million shares, up from 6.25 million shares in 2017Q4. Also, the number of institutional investors holding Ani Pharmaceuticals Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 12 Reduced: 42 Increased: 40 New Position: 37.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $780.73 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It currently has negative earnings. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

The stock decreased 1.46% or $0.98 during the last trading session, reaching $66.24. About 113,796 shares traded or 38.59% up from the average. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 31.37% since June 14, 2017 and is uptrending. It has outperformed by 18.80% the S&P500.

Analysts await ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to report earnings on August, 2. They expect $1.21 EPS, up 37.50 % or $0.33 from last year’s $0.88 per share. ANIP’s profit will be $14.26 million for 13.69 P/E if the $1.21 EPS becomes a reality. After $1.23 actual EPS reported by ANI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -1.63 % negative EPS growth.

1492 Capital Management Llc holds 1.63% of its portfolio in ANI Pharmaceuticals, Inc. for 36,321 shares. Mangrove Partners owns 376,314 shares or 1.43% of their US portfolio. Moreover, Perkins Capital Management Inc has 1.42% invested in the company for 27,000 shares. The New York-based Consonance Capital Management Lp has invested 0.76% in the stock. Regent Investment Management Llc, a Kentucky-based fund reported 35,965 shares.

Since January 1, 0001, it had 0 insider buys, and 10 selling transactions for $18.16 million activity.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Ratings Coverage

Ratings analysis reveals 100% of ANI Pharmaceuticals’s analysts are positive. Out of 2 Wall Street analysts rating ANI Pharmaceuticals, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $82 while the high is $8500. The stock’s average target of $83.50 is 26.06% above today’s ($66.24) share price. ANIP was included in 2 notes of analysts from February 28, 2018. As per Monday, June 11, the company rating was initiated by Cantor Fitzgerald. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, February 28.

More recent ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were published by: which released: “ANI Pharma (ANIP) Appoints Thomas J. Haughey, David B. Nash and Patrick D. Walsh to Board” on June 05, 2018. Also published the news titled: “Premarket analyst action – healthcare” on June 12, 2018.‘s news article titled: “ANI Shareholders Elect Three New Members to the Board of Directors” with publication date: June 05, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.